Labcorp Holdings Inc. (LH)
NYSE: LH · Services-Medical Laboratories · Burlington, NC · filing with the SEC since 1994
Grade5.7
◀ Past 5.5● Present 6.6▶ Future 4.8
Who owns Labcorp Holdings Inc.
As filed with the SECHolders of 5% or more
2
Blackrock, Inc. holds 7.6% of Common Stock, as its SCHEDULE 13G/A filed Apr 24, 2025 says.
Directors and officers
23
report now, of 41 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 24, 2025 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Apr 28, 2026 · Common Stock
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
What LH reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Empire City Laboratories, Inc
A company bought · acquisition · owns, named in the 10-K filed Feb 24, 2026
Parkview Health Systems, Inc.
A company bought · acquisition · owns, named in the 10-K filed Feb 24, 2026
89 subsidiaries in 1 country, from the list filed with the 10-K filed Feb 24, 2026.
Insider tradesForm 4
22sales
0purchases
14sales on a scheduled plan
10people selling
$11.7Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window10 of 41 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Schechter Adam H | President & CEO | 4 | $6.9M | 3 | 0 | $0 |
| Caveney Brian J | EVP, Pres of BLS, CMO & CSO | 2 | $1.2M | 0 | 0 | $0 |
| Wilkinson Peter J | SVP, Chief Accounting Officer | 4 | $1.1M | 2 | 0 | $0 |
| Anderson Kerrii B | director | 1 | $1.0M | 1 | 0 | $0 |
| Parham Richelle P | director | 1 | $400,000 | 0 | 0 | $0 |
| Meltzer Jonathan C | EVP, COO | 4 | $300,000 | 4 | 0 | $0 |
| Summy Amy B. | EVP, Chief Marketing Officer | 1 | $300,000 | 0 | 0 | $0 |
| Vaughn Bryan T | EVP and President, Diagnostics | 2 | $200,000 | 2 | 0 | $0 |
| Kyle Kathryn W | EVP, Chief Legal Officer | 2 | $200,000 | 2 | 0 | $0 |
| Van Der Vaart Sandra D | EVP, Corporate Affairs | 1 | $200,000 | 0 | 0 | $0 |